Arena Pharmaceutical Inc. (ARNA) announced after the bell Monday that its Phase 2 study of Ralinepag demonstrated a statistically significant absolute change from baseline in pulmonary vascular resistance compared to placebo in patients with pulmonary arterial hypertension.
from RTT - Before the Bell http://ift.tt/2sPnXx7
via IFTTT
No comments:
Post a Comment